Scott Bizily - 16 Oct 2025 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Signature
/s/ Scott Bizily
Issuer symbol
FDMT
Transactions as of
16 Oct 2025
Net transactions value
-$9,859
Form type
4
Filing time
20 Oct 2025, 19:51:45 UTC
Previous filing
14 Oct 2025
Next filing
27 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bizily Scott Chief Legal Officer C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE /s/ Scott Bizily 20 Oct 2025 0001920738

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $6,769 +1,635 +32% $4.14 6,823 16 Oct 2025 Direct F1
transaction FDMT Common Stock Sale $16,628 -1,635 -24% $10.17 5,188 16 Oct 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -1,635 -2.1% $0.000000 76,865 16 Oct 2025 Common Stock 1,635 $4.14 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
F2 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.